## Supplemental Table 3

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **CD39 ( ENTPD-1)** | | **CD73 ( NT5E)** | |
| **HUGO** | **R** | **p** | **R** | **p** |
| AIF-1 | 0.582 | 3.1x10-27 | 0.404 | 1.2x10-12 |
| ANPEP | 0.286 | 9.2x10-7 | 0.259 | 9.1x10-6 |
| CCR2 | 0.481 | 6.9x10-18 | 0.320 | 3.2x10-8 |
| CD14 | 0.579 | 7.1x10-27 | 0.452 | 9.8x10-16 |
| CD33 | 0.488 | 1.8x10-18 | 0.148 | 0.01 |
| CD34 | 0.233 | 6.9x10-5 | 0.181 | 2.2x10-3 |
| CD38 | 0.337 | 5.4x10-9 | 0.201 | 6.6x10-4 |
| CD68 | 0.364 | 2.4x10-10 | 0.272 | 3.1x10-6 |
| CD80 | 0.239 | 4.6x10-5 | 0.042 | 0.48 |
| CD163 | 0.605 | 7.2x10-30 | 0.383 | 2.1x10-11 |
| CSF2RA | 0.426 | 5.7x10-14 | 0.302 | 2x10-7 |
| CSF2RB | 0.633 | 2.4x10-33 | 0.392 | 6.9x10-12 |
| CXCR2 | 0.207 | 4.5x10-4 | 0.207 | 4.3x10-4 |
| HLA | 0.440 | 6.3x10-15 | 0.407 | 8.9x10-13 |
| IL4R | 0.454 | 6.6x10-16 | 0.508 | 4.6x10-20 |
| ITGAM | 0.554 | 2.4x10-24 | 0.439 | 7.5x10-15 |
| ITGAX | 0.576 | 1.5x10-26 | 0.259 | 9.1x10-6 |
| KDR | 0.359 | 4.3x10-10 | 0.151 | 0.01 |
| LY75 | 0.055 | 0.36 | 0.288 | 7.7x10-7 |
| LY96 | 0.641 | 2.4x10-34 | 0.492 | 9.1x10-19 |
| MNDA | 0.604 | 1.1x10-29 | 0.482 | 5.6x10-18 |
| MS4A7 | 0.601 | 2.5x10-29 | 0.429 | 3.6x10-14 |
| PTPRC | 0.678 | 1.2x10-39 | 0.376 | 5.5x10-11 |
| TEK | 0.327 | 1.6x10-8 | 0.234 | 6.8x10-5 |

**Supplemental Table 3: Gene expression correlation analysis. Correlation between CD39 (ENTPD-1) or CD73 (NT5E) and phenotypic markers on human myeloid cells.** Gene expression data from 285 ovarian cancer tissues from the AOCS (Australian Ovarian Cancer Study) were screened for genes correlating with the presence of CD39 (ENTPD-1) or CD73 (NT5E). Pairwise correlation analyses indicated positive correlations between almost all phenotypical markers described for MDSC (Talmadge and Gabrilovich, 2013) and the ectoenzymes CD73 and CD39.